All-cause and cause-specific mortality in psoriasis: A systematic review and meta-analysis - 12/04/19
Abstract |
Background |
An overview of mortality risk associated with psoriasis is lacking.
Objective |
To perform a systematic review and meta-analysis of mortality risk in psoriasis.
Methods |
We included studies reporting all-cause or cause-specific mortality risk estimates in psoriasis patients compared with general population or subjects free of psoriasis. We calculated pooled relative risks (RRs) and 95% confidence intervals (CIs).
Results |
We included 12 studies. The pooled RRs for all-cause mortality were 1.21 (95% CI 1.14-1.28) in psoriasis, 1.13 (95% CI 1.09-1.16) in mild psoriasis, and 1.52 (95% CI 1.35-1.71) in severe psoriasis. The pooled RRs for cardiovascular mortality were 1.15 (95% CI 1.09-1.21) in psoriasis, 1.05 (95% CI 0.92-1.20) in mild psoriasis, and 1.38 (95% CI 1.09-1.74) in severe psoriasis. For noncardiovascular causes, mortality risk from liver disease, kidney disease, and infection was significantly increased in psoriasis, regardless of disease severity. The mortality risk in liver and kidney disease was the highest. There was also a significantly increased mortality risk associated with neoplasms in severe psoriasis patients and chronic lower respiratory disease in all and mild psoriasis patients.
Limitations |
Although associations were consistent, their magnitude was heterogenous.
Conclusion |
Psoriasis is associated with an increased risk for mortality from all causes (in a dose-response manner with disease severity) and from several specific causes.
Le texte complet de cet article est disponible en PDF.Key words : cardiovascular disease, cause of death, infectious disease, kidney disease, liver disease, malignancy, mortality, psoriasis, respiratory disease, systematic review
Abbreviations used : CI, RR, SMR
Plan
Funding sources: None. |
|
Conflicts of interest: None disclosed. |
|
Reprints not available from the authors. |
Vol 80 - N° 5
P. 1332-1343 - mai 2019 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?